Hereditary Angioedema Market – Efficient Disease Management for Orphan Disease
Hereditary angioedema (HAE) is a rare disorder related with the immune system. The life-threatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) causing the blood vessels to dilate. The symptoms of the disease include recurrent episodes of edema in various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I HAE, Type II HAE and Type III HAE based on the reduction in its synthesis of inhibitor or the formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE cases result from a spontaneous mutation of the C1-inhibitor gene at conception.
The global hereditary angioedema market was valued at US$ 1,563.7 million in 2016 and is expected to witness a robust CAGR of 9.1% over the forecast period (2017 - 2025).
Figure 1. Global Hereditary Angioedema Market (US$ Mn), by Region, 2016
Increasing prevalence and rising awareness of hereditary angioedema to augment market growth
The increasing number of hereditary angioedema cases and the hereditary nature giving the disease an ability to pass the defective gene to the future generations is expected to propel market growth. According to the survey by International Hereditary Angioedema Organization (HAEi), 2015, the global prevalence of hereditary angioedema is estimated to be around 1 in 10,000 to 50,000 people, meaning that around a quarter million people suffer globally from this rare and life threatening deficiency condition. Also, according to National Association for Rare Disorders, 2016, the risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child. North America dominates the hereditary angioedema market, owing to the higher number of drugs approved in the regions, presence of major manufacturers and the presence of various organizations serving HAE patients. In 2017, the U.S. Food and Drug Administration (FDA) approved Haegarda (C1-esterase inhibitor) manufactured by CSL Behring for routine prophylaxis to prevent HAE attacks in adolescent and adult patients. However, the rare occurrence of the disease make it difficult for efficient diagnosis and either opt for alternative therapies to control the disease, thus accounting to be the major factors restraining the market growth.
Increasing support from non-profit organizations towards intensive research is expected to accelerate the market
The organizations are focusing on increasing global HAE awareness by educating and empowering patient, providing access to suitable therapy/treatment. The organizations are also working towards intensive research to find a cure. For instance, the non-profit organization named HAEi is dedicated towards spreading awareness of C1-inhibitor deficiencies and to improve diagnosis, facilitating access to reimbursement of the HAE therapies, enabling lifelong health for the global patients. The organization also initiated the Global Access Program (HAEi GAP) in 2015, to provide the access to the approved HAE medications in countries where modern therapies are otherwise unavailable. Moreover, the non-profit organization- US Hereditary Angioedema Association is committed to advance and conduct clinical research designed to improve the lives of HAE patients. The major players operating the global hereditary angioedema market include CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies and Attune Pharmaceuticals, Inc.
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 58 market data tables and 32 figures on "Hereditary Angioedema Market - Global forecast to 2025”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.